Abcodia is a pioneering UK company engaged in the clinical and commercial development of novel, validated tests for the early detection of cancer. The company's first product, launched in 2015, is the ROCA® test for the early detection of ovarian cancer.
Abcodia’s offerings are based on expertise in measuring and modelling dynamic changes over time of serum-based biomarkers before cancer is clinically diagnosed, and it maintains exclusive commercial access to a biobank of 5 million samples donated from 200,000 individuals over a 10-year period. Abcodia holds strategic collaborations with leading global organizations including Cancer Research UK, University College London and other academic and industry partners.
The ROCA® test
The ROCA® test refers to the Risk of Ovarian Cancer Algorithm, invented by academic gynaecological oncologist, Professor Ian Jacobs (University New South Wales; Principal Investigator of the UKCTOCS trial), and Dr Steve Skates (Massachusetts General Hospital and Harvard University; Statistician).
Through routine testing, the ROCA® test assesses the likelihood of a women having ovarian cancer and is used clinically to refer women for a diagnostic ultrasound test. It was developed using analysis of years of serial blood chemistry CA125 and clinical data derived from women who developed ovarian cancer those who did not.
It was then evaluated in the largest cancer screening trial in the world involving over 200,000 women and up to 14 years of real world experience. Results published in December 2015 from the UKCTOCS trial showed that ovarian cancer screening using ROCA® could reduce mortality by 20%.